Adverum Biotechnologies I...

NASDAQ: ADVM · Real-Time Price · USD
2.82
0.05 (1.81%)
At close: Aug 15, 2025, 3:59 PM
2.81
-0.35%
After-hours: Aug 15, 2025, 06:04 PM EDT

Adverum Biotechnologies Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a n/a 1M n/a n/a -3.6M n/a n/a 3.6M n/a n/a n/a n/a -7.5M n/a n/a 7.5M
Cost of Revenue
535K 683K 7.04M 890K 956K 997K 1.01M 1.51M 7.04M n/a 1.71M 1.79M 1.6M 1.43M 7.5M 962K 1.2M n/a
Gross Profit
-535K -683K -10.64M 110K -956K -997K -4.61M -1.51M -7.04M 3.6M -1.71M -1.79M -1.6M -1.43M -15M -962K -1.2M 7.5M
Operating Income
-49.85M -48.22M 63.3M -30.72M -32.9M -28.14M -31.11M -34.53M -33.06M -30.24M -33.94M -41.04M -44.02M -38.13M -34.42M -38.52M -44.54M -28.64M
Interest Income
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Pretax Income
-49.19M -47.02M -32.87M -27.13M -30.5M -24.79M -29.8M -32.87M -31.49M -29.04M -32.72M -40.11M -43.74M -37.89M -34.41M -38.36M -44.33M -28.44M
Net Income
-49.19M -47.02M -60.53M -27.13M -18.48M -24.79M -23.71M -32.88M -31.51M -29.06M -32.74M -40.13M -43.76M -37.91M -34.41M -38.36M -44.33M -28.44M
Selling & General & Admin
12.73M 19.47M 13.79M 9.78M 11.03M 11.73M 9.87M 12.28M 12.47M 12.78M 11.74M 17.19M 13.76M 15.17M 11.89M 14.45M 21.93M 16.16M
Research & Development
37.13M 28.75M 24.09M 20.44M 17.1M 15.41M 15.08M 20.74M 20.6M 21.06M 22.2M 23.85M 30.27M 22.96M 22.52M 24.07M 22.61M 19.98M
Other Expenses
n/a -683K 16.79M 610K n/a n/a 990K n/a 1.58M n/a 1.22M 923K 283K 244K 10K 160K 205K 207K
Operating Expenses
49.85M 47.54M 54.67M 30.83M 28.13M 27.14M 25.94M 33.02M 33.06M 33.84M 33.94M 41.04M 44.02M 38.13M 34.42M 38.52M 44.54M 36.14M
Interest Expense
n/a n/a n/a n/a n/a n/a 1.2M n/a n/a n/a 80.41M n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a 7.24M 303K -1.01M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
49.85M 48.22M 65.22M 31.72M 29.08M 28.14M 26.95M 34.53M 33.06M 33.84M 33.94M 41.04M 44.02M 38.13M 34.42M 38.52M 44.54M 36.14M
Income Tax Expense
n/a n/a n/a n/a n/a n/a -1.13M 17K 21K 17K 19K 17K 19K 19K n/a n/a n/a n/a
Shares Outstanding (Basic)
21.01M 20.94M 20.9M 20.88M 20.85M 16.48M 57.98M 57.98M 57.98M 57.98M 57.98M 99.47M 99M 98.6M 98.13M 98.13M 98.02M 97.75M
Shares Outstanding (Diluted)
21.01M 20.94M 20.9M 20.88M 20.85M 16.48M 57.98M 57.98M 57.98M 57.98M 57.98M 99.47M 99M 98.6M 98.13M 98.13M 98.02M 97.75M
EPS (Basic)
-2.34 -2.25 -1.96 -1.3 -0.89 -1.5 -0.41 -0.57 -0.54 -0.5 -0.56 -0.4 -0.44 -0.38 -0.35 -0.39 -0.45 -0.29
EPS (Diluted)
-2.34 -2.25 -1.96 -1.3 -0.89 -1.5 -0.41 -0.57 -0.54 -0.5 -0.56 -0.4 -0.44 -0.38 -0.35 -0.39 -0.45 -0.29
EBITDA
-48.66M -46.34M -40.12M -26.24M -29.54M -26.15M -24.63M -33.02M -24.45M -28.65M -31M -38.33M -42.14M -36.46M -33.09M -37.4M -43.14M -27.27M
EBIT
-49.19M -47.02M -40.93M -27.13M -30.5M -27.15M -25.64M -34.53M -33.06M -30.24M -33.94M -41.04M -44.02M -38.13M -34.42M -38.52M -44.54M -28.64M
Depreciation & Amortization
535K 683K 810K 890K 956K 997K 1.01M 1.51M 7.04M 1.59M 1.71M 1.79M 1.6M 1.43M 1.32M 962K 1.2M 1.17M